| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CYTOGFR.2010.02.004 |
| P8608 | Fatcat ID | release_jlmb6msiafapdguuuxfbl42sja |
| P932 | PMC publication ID | 3109423 |
| P698 | PubMed publication ID | 20226717 |
| P5875 | ResearchGate publication ID | 41942238 |
| P2093 | author name string | Hiroshi Nakashima | |
| Balveen Kaur | |||
| E A Chiocca | |||
| P2860 | cites work | PILRalpha is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B | Q24313362 |
| Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5 | Q28303765 | ||
| Mammalian neural stem cells | Q29547657 | ||
| Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma | Q30493691 | ||
| Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response | Q30573416 | ||
| Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas | Q33382708 | ||
| Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies | Q33519052 | ||
| Stem cells for ischemic brain injury: a critical review | Q33957236 | ||
| Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene. | Q34134316 | ||
| Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas | Q34297434 | ||
| Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. | Q34433743 | ||
| Separation of receptor-binding and profusogenic domains of glycoprotein D of herpes simplex virus 1 into distinct interacting proteins | Q35676817 | ||
| Efficient adenoviral-mediated gene delivery into porcine mesenchymal stem cells | Q45861655 | ||
| Development of adenovirus serotype 35 as a gene transfer vector | Q45863407 | ||
| Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors | Q45869203 | ||
| Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas | Q45869995 | ||
| Quantitation of HSV mass distribution in a rodent brain tumor model. | Q45872410 | ||
| Gene transfer to cervical cancer with fiber-modified adenoviruses | Q45876622 | ||
| Homing properties of adipose-derived stem cells to intracerebral glioma and the effects of adenovirus infection | Q48888957 | ||
| An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor | Q48945443 | ||
| Making a tumour's bed: glioblastoma stem cells and the vascular niche. | Q51977217 | ||
| A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. | Q52537791 | ||
| Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. | Q55480207 | ||
| Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors | Q64378688 | ||
| An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy | Q64380394 | ||
| Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy | Q80162686 | ||
| Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan | Q81414181 | ||
| Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas | Q35827956 | ||
| A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. | Q36158701 | ||
| Development of transcriptionally regulated oncolytic adenoviruses | Q36318182 | ||
| The therapeutic potential of neural stem cells | Q36500191 | ||
| Mesenchymal stem cells: lineage, plasticity, and skeletal therapeutic potential | Q36672124 | ||
| Oncolytic viruses driven by tumor-specific promoters | Q36754456 | ||
| Angiogenesis in brain tumours | Q36887534 | ||
| Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo | Q37096766 | ||
| Stem and progenitor cell-mediated tumor selective gene therapy | Q37120161 | ||
| Concise review: adult multipotent stromal cells and cancer: risk or benefit? | Q37128260 | ||
| Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells | Q37134013 | ||
| The use of mesenchymal (skeletal) stem cells for treatment of degenerative diseases: current status and future perspectives. | Q37252080 | ||
| Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas | Q37461117 | ||
| Cell carriers for oncolytic viruses: Fed Ex for cancer therapy | Q37582184 | ||
| Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma | Q38507328 | ||
| Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. | Q38922636 | ||
| Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells | Q39166193 | ||
| Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob | Q39577664 | ||
| Neural stem cell tropism to glioma: critical role of tumor hypoxia. | Q39906167 | ||
| Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. | Q39953338 | ||
| Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma | Q40025607 | ||
| Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus | Q40034989 | ||
| Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses | Q40105169 | ||
| Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy | Q40154007 | ||
| Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma | Q40160544 | ||
| Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. | Q40197211 | ||
| Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells | Q40216419 | ||
| Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses | Q40302572 | ||
| Endowing human adenovirus serotype 5 vectors with fiber domains of species B greatly enhances gene transfer into human mesenchymal stem cells. | Q40350307 | ||
| Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival. | Q40448344 | ||
| Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy | Q40555826 | ||
| Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells | Q40570664 | ||
| In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors | Q42818740 | ||
| Ischemia-induced neurogenesis of neocortical layer 1 progenitor cells | Q43206633 | ||
| Novel compound enables high-level adenovirus transduction in the absence of an adenovirus-specific receptor | Q43702092 | ||
| In vitro differentiation of transplantable neural precursors from human embryonic stem cells | Q43814659 | ||
| Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. | Q43866864 | ||
| Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses | Q43941683 | ||
| Gene therapy of experimental brain tumors using neural progenitor cells | Q44761775 | ||
| Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. | Q45396446 | ||
| Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma. | Q45408133 | ||
| Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. | Q45748695 | ||
| Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. | Q45755851 | ||
| P433 | issue | 2-3 | |
| P921 | main subject | oncolytic virus | Q1560099 |
| P304 | page(s) | 119-126 | |
| P577 | publication date | 2010-03-11 | |
| P1433 | published in | Cytokine and Growth Factor Reviews | Q15763303 |
| P1476 | title | Directing systemic oncolytic viral delivery to tumors via carrier cells | |
| P478 | volume | 21 |
| Q37316842 | An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors |
| Q39319601 | An intravenous stimulus package for oncolytic virotherapy |
| Q38241666 | Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses |
| Q36849213 | Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors. |
| Q34318157 | Current status of gene therapy for brain tumors. |
| Q36549443 | EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA |
| Q38378499 | Engineering Stem Cells for Biomedical Applications. |
| Q38123856 | Engineering antiphagocytic biomimetic drug carriers |
| Q40060078 | Gene Delivery in Neuro-Oncology |
| Q40092902 | Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus. |
| Q49514696 | Matrix metalloproteinase-1 facilitates MSC migration via cleavage of IGF-2/IGFBP2 complex |
| Q26853374 | Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment |
| Q36092724 | Mesenchymal stem cells engineered for cancer therapy |
| Q40511505 | Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL. |
| Q98292352 | Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma |
| Q37971309 | Neurotransplantation: lux et veritas, fiction or reality? |
| Q30427305 | Noninvasive pulsed focused ultrasound allows spatiotemporal control of targeted homing for multiple stem cell types in murine skeletal muscle and the magnitude of cell homing can be increased through repeated applications |
| Q38848223 | Oncolytic Immunotherapy for Treatment of Cancer |
| Q37990940 | Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions |
| Q38207011 | Oncolytic viruses and their application to cancer immunotherapy |
| Q92099101 | Oncolytic viruses: overcoming translational challenges |
| Q38025696 | Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy. |
| Q36597119 | Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer |
| Q35785494 | Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus |
| Q38647883 | Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy |
| Q26765439 | Retargeting Strategies for Oncolytic Herpes Simplex Viruses |
| Q37982062 | Retargeting of viruses to generate oncolytic agents |
| Q34240433 | Stem cells as therapeutic vehicles for the treatment of high-grade gliomas |
| Q37420576 | Strategies in gene therapy for glioblastoma. |
| Q37547783 | Switching a replication-defective adenoviral vector into a replication-competent, oncolytic adenovirus |
| Q36544212 | Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases |
| Q39003657 | The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity |
| Q24597894 | Thunder and lightning: immunotherapy and oncolytic viruses collide |
| Q51846287 | Tumor Restrictions to Oncolytic Virus. |
| Q30830225 | Tumor-specific delivery of biologics by a novel T-cell line HOZOT. |
| Q27021839 | Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer |
| Q89797616 | p19Arf sensitizes B16 melanoma cells to interferon-β delivered via mesenchymal stem cells in vitro |
Search more.